疫苗佐剂的全球市场规模、份额和成长分析：按类型和给药途径分类 - 产业预测（2024-2031）

Global Vaccine Adjuvants Market Size, Share, Growth Analysis, By Type(Pathogen-Based Adjuvants and Particulate Adjuvants), By Route of Administration(Intramuscular Route, and Intradermal Route) - Industry Forecast 2024-2031

出版日期: 2024年03月27日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预测期内（2024-2031年），全球疫苗佐剂市场规模预计为8.9323亿美元，从2023年的10.1819亿美元成长到2031年的29.0245亿美元，预计复合年增长率为13.99% 2018 年）。

老年人和肥胖人口的增加是推动疫苗佐剂市场成长的关键因素之一。医疗基础设施投资的增加正在推动对疫苗佐剂的需求。促成疫苗佐剂市场有吸引力的成长前景的其他辅助因素包括技术创新、氢氧化铝佐剂的改进以及个人可支配收入。新兴低度开发国家不利的报销情况导致的技术障碍可能会阻碍疫苗佐剂市场的扩张。监管核准流程的延长和监管合规标准的严格预计将进一步阻碍疫苗佐剂市场的成长速度。由于佐剂的副作用，市场成长的步伐可能会进一步放缓。製造这些药物的高成本也被认为是市场成长的障碍。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2021年）
主要市场参与者所采取的策略
关键成功策略
近期市集活动
主要企业市场占有率（2021年）

主要企业简介

CSL Limited（Australia）
GlaxoSmithKline plc（United Kingdom）
Novavax, Inc.（US）
SEPPIC（France）
Agenus Inc.（US）
InvivoGen（US）
Brenntag Biosector（Denmark）
Avanti Polar Lipids, Inc.（US）
Vaxine Pty Ltd.（Australia）
SPI Pharma（US）
OZ Biosciences（France）
CureVac AG（Germany）
Adjuvatis（France）
Advanced BioAdjuvants Corporation（US）
Adjuvance Technologies Inc.（US）
SDA Bio（Italy）
Bio Products Laboratory Ltd.（United Kingdom）
GSK Vaccines GmbH（Germany）
Mucosis BV（Netherlands）
NanoBio Corporation（US）

简介目录

Product Code: SQMIG35I2155

Global Vaccine Adjuvants Market size was valued at USD 893.23 million in 2022 and is poised to grow from USD 1018.19 million in 2023 to USD 2902.45 million by 2031, growing at a CAGR of 13.99% during the forecast period (2024-2031).

The growing number of elderly and obese people is one of the main factors propelling the vaccine adjuvants market's growth. Growing investments in healthcare infrastructure are driving the demand for vaccination adjuvants. Additional secondary factors that will contribute to the vaccination adjuvant market's attractive growth prospects are technological innovations, improvements in adjuvants based on aluminum hydroxide, and individual disposable income. Technical obstacles resulting from the unfavorable reimbursement scenario in developing and underdeveloped nations would impede the expansion of the vaccine adjuvants market. Prolonged regulatory approval processes and strict regulatory compliance criteria would further impede the vaccine adjuvant market growth rate. The market's growth pace will be further slowed by adjuvant side effects. The high manufacturing costs of these medications will also be a barrier in the growth of the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Adjuvants Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Adjuvants Market Segmental Analysis

Global Vaccine Adjuvants market is segmented on the basis of Product Type, Route of Administration, Diseases, Application, and region. By Product Type, the market is segmented into Adjuvant Emulsions, Pathogen Components, Particulate Adjuvants, Combination Adjuvants, and others. By Route of Administration, the market is segmented into Oral, Intramuscular, Intranasal, Subcutaneous, Intradermal, Others. By Diseases, the market is segmented into Cancer, Infectious Diseases, Others. By Application, the market is segmented into Research, and Commercial. The market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America as according region.

Drivers of the Global Vaccine Adjuvants Market

Because infectious diseases are becoming more common, it is expected that the global market for vaccine adjuvants would grow faster than average over the course of the forecast period. Immunization, for example, is one of the best ways to avoid infectious diseases. Globally, only COVID-19 claims more lives than tuberculosis (TB), which is still a major health risk because of drug-resistant TB strains. The World Health Organization (WHO) reports that over 1.6 million people died from tuberculosis (TB) in 2021.

Restraints in the Global Vaccine Adjuvants Market

The high toxicity and adverse effects of vaccination adjuvants are expected to impede the growth of the global vaccine adjuvants market. As per the CDC, adjuvanted vaccines have the potential to cause increased local symptoms like swelling, redness, and discomfort at the injection site, as well as increased systemic reactions including fever, body aches, and chills, as compared to non-adjuvanted vaccines. The adjuvants have a range of mild to severe side effects and can also occasionally cause adverse outcomes.

Market Trends of the Global Vaccine Adjuvants Market

The primary drivers of the global vaccine adjuvants market are the increased prevalence of allergies and infectious illnesses like cancer, HIV/AIDS, human papillomavirus (HPV), and tuberculosis. The current demand for innovative therapies for deadly diseases that are on the rise has led to the development of vaccinations with long-lasting effects on immunization. Currently undergoing clinical studies include AS01, ISCOM & ISCOMMATRIX, and AS02, which are examples of novel adjuvants developed by significant manufacturers. Governments from several countries are also advancing adjuvant technologies for human usage and vaccination programs. They are also concentrating on enhancing the healthcare system and obtaining funding for the investigation and development of new treatments.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Vaccine Adjuvants Market by Type

Market Overview
Pathogen-Based Adjuvants and Particulate Adjuvants

Global Vaccine Adjuvants Market by Route of Administration

Market Overview
Intramuscular Route
and Intradermal Route

Global Vaccine Adjuvants Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEPPIC (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InvivoGen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Brenntag Biosector (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Avanti Polar Lipids, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxine Pty Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SPI Pharma (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OZ Biosciences (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CureVac AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adjuvatis (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advanced BioAdjuvants Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adjuvance Technologies Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SDA Bio (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio Products Laboratory Ltd. (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GSK Vaccines GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mucosis B.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NanoBio Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments